SUPPLEMENTARY INFORMATION FOR

Early Post-operative Urine and Serum Biomarkers Predict Acute Kidney Injury and Poor Outcomes after Pediatric Cardiac Surgery

Item **Reported on** No Recommendation Page # Title and abstract (a) Indicate the study's design with a commonly used term in the title 1 1,2 or the abstract (b) Provide in the abstract an informative and balanced summary of 2 what was done and what was found Introduction Background/rationale 2 Explain the scientific background and rationale for the investigation 3 being reported Objectives 3 State specific objectives, including any prespecified hypotheses 3 Methods 12 Study design 4 Present key elements of study design early in the paper 5 Describe the setting, locations, and relevant dates, including periods of Setting 12 recruitment, exposure, follow-up, and data collection (a) Give the eligibility criteria, and the sources and methods of Participants 6 12 selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed N/A and unexposed Clearly define all outcomes, exposures, predictors, potential Variables 7 12-15 confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ 8 For each variable of interest, give sources of data and details of 12-15 methods of assessment (measurement). Describe comparability of measurement assessment methods if there is more than one group 9 Bias Describe any efforts to address potential sources of bias 12-14 10 Study size Explain how the study size was arrived at Below Quantitative variables Explain how quantitative variables were handled in the analyses. If 14,15 11 applicable, describe which groupings were chosen and why Statistical methods (a) Describe all statistical methods, including those used to control for 12 14,15 confounding (b) Describe any methods used to examine subgroups and interactions 14,15 (c) Explain how missing data were addressed NR (d) If applicable, explain how loss to follow-up was addressed N/A (e) Describe any sensitivity analyses 14,15 Results (a) Report numbers of individuals at each stage of study—eg numbers Participants 13 Supplementary potentially eligible, examined for eligibility, confirmed eligible, included Figure 1 in the study, completing follow-up, and analyzed (b) Give reasons for non-participation at each stage Supplementary Figure 1

Supplementary Table 1: STROBE checklist

		(c) Consider use of a flow diagram	Supplementary Figure 1
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical,	Table 1
		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable	NR
		of interest	
		(c) Summarize follow-up time (e.g., average and total amount)	4,5
Outcome data	15	Report numbers of outcome events or summary measures over time	Table 2
			Figures 1, 2, 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	Table 2
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	Table 2
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	Table 2
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	6,7
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarize key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of	9-11
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	8-10
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalizability	21	Discuss the generalizability (external validity) of the study results	8-11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	16
		study and, if applicable, for the original study on which the present	
		article is based	

Our sample size calculations were based upon detecting the odds ratio of the 5th biomarker quintile developing AKI compared to the 1st biomarker quintile. Assuming an overall AKI rate of AKI of 17%, our sample of 311 patients provided over 80% power to detect an odds ratio of at least 3.5 or more using a two-tailed alpha of 0.05.

	Severe AKI				No AKI						
	P25*	Mean	Median	P75*	SD	P25*	Mean	Median	P75*	SD	P-value [†]
Urine IL-18 (pg/mL)											
Pre-op	10.41	80.06	32.69	61.80	141.35	7.33	73.74	19.86	46.77	248.57	0.0387
Day 1 0-6 Hours	62.63	645.85	244.00	612.31	1059.12	17.33	238.30	53.47	200.22	570.62	<0.0001
Day 1 6-12 Hours	108.91	278.41	201.96	317.12	310.59	35.06	129.28	64.12	140.70	210.38	<0.0001
Day 1 12-18 Hours	48.74	416.66	114.41	315.80	812.94	22.40	106.96	51.63	116.59	196.61	<0.0001
Day 2	7.58	205.00	25.22	85.57	675.28	6.27	39.99	14.92	47.40	62.55	0.0369
Day 3	4.85	59.96	12.55	27.17	195.75	4.02	31.30	8.42	24.98	72.57	0.2905
Urine NGAL (ng/mL)											
Pre-op	3.87	8.89	5.58	9.23	10.39	1.96	36.48	4.40	9.45	248.91	0.1028
Day 1 0-6 Hours	16.05	349.70	40.70	216.03	686.93	3.23	119.43	9.62	34.38	471.54	<0.0001
Day 1 6-12 Hours	9.81	130.51	17.31	59.16	468.18	4.45	58.36	8.31	18.93	323.95	<0.0001
Day 1 12-18 Hours	8.70	60.24	20.06	58.81	135.45	3.10	42.24	7.84	17.72	186.37	<0.0001
Day 2	4.97	116.38	10.61	33.00	575.54	3.99	29.74	7.85	15.60	115.38	0.0441
Day 3	3.83	53.75	8.70	37.79	195.35	4.25	22.91	8.58	19.73	43.47	0.6020
Plasma NGAL (ng/mL)											
Pre-op	60.00	98.64	60.00	135.90	63.83	60.00	94.70	75.83	106.42	54.76	0.2295
Day 1 0-6 Hours	95.36	218.71	169.76	266.22	201.05	88.64	171.04	144.95	212.57	105.74	0.1774
Day 2	63.04	171.02	119.49	201.36	163.95	60.00	126.49	91.84	163.54	92.47	0.1238
Day 3	60.00	171.88	117.03	182.79	186.38	60.00	126.01	91.18	150.73	98.31	0.2334
Serum Creatinine (mg/dL)											
Pre-op	0.3	0.351	0.3	0.4	0.162	0.3	0.441	0.4	0.5	0.155	<.0001
Day 1 0-6 Hours	0.4	0.545	0.4	0.6	0.298	0.4	0.509	0.5	0.6	0.173	0.3749
Day 2	0.5	0.776	0.7	0.9	0.403	0.4	0.517	0.5	0.6	0.187	<.0001
Day 3	0.4	0.624	0.5	0.6	0.53	0.3	0.445	0.4	0.5	0.165	0.0111

Supplementary Table 2: Summary Statistics of biomarkers by Severe AKI*


*P25 = 25th percentile, P75 = 75th percentile


⁺P-value from Wilcoxon rank sum test

* AKI was defined as the receipt of acute dialysis or the doubling of serum creatinine during hospitalization.

Supplementary Table 3: Performance of first post-operative biomarkers by site for Severe AKI

AUC (SE)	Cincinnati	Montreal	Yale	All
Urine IL-18	0.74 (0.05)	0.76 (0.09)	0.72 (0.11)	0.72 (0.04)
Urine NGAL	0.71 (0.05)	0.76 (0.00)	0.67 (0.12)	0.71 (0.04)
Plasma NGAL	0.58 (0.06)	0.55 (0.10)	0.51 (0.12)	0.56 (0.05)
Serum Creatinine	0.46 (0.05)	0.51 (0.09)	0.48 (0.12)	0.46 (0.04)





[†]AKI (RIFLE R) was defined by the receipt of acute dialysis or an increase of 50% in serum creatinine during the hospital stay. Severe AKI was defined by the receipt of acute dialysis or a doubling in serum creatinine during the hospital stay.

*Individual Biomarkers and ROC Regression results are from the first post-operative biomarker sample.

[‡]Biomarker Combinations: Highest AUC with 2 biomarkers for AKI and Severe AKI is Urine IL-18 on Day 1 6-12 Hours and Urine IL-18 Day 1 12-18 Hours. Highest AUC with 3 biomarkers for AKI is Urine IL-18 Day 1 6-12 Hours, Urine NGAL 12-18 Hours and Plasma NGAL Day 2; for Severe AKI is Urine IL-18 Day 1 0-6 Hours, Urine IL-18 Day 1 6-12 Hours and Urine IL-18 Day 1 12-18 Hours.

 $Although higher AUCs are in the groups of Age \geq 2 years, this difference is not statistically significant.$